The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 25, 2025
Filed:
Oct. 23, 2019
Applicant:
Bristol-myers Squibb Company, Princeton, NJ (US);
Inventors:
Sabine Maier, Lawrenceville, NJ (US);
Abderrahim Oukessou, Skillman, NJ (US);
Nicholas Allan Botwood, Princeton, NJ (US);
Kelly L. Covello, Philadelphia, PA (US);
Michael V. Mandola, Williamstown, NJ (US);
Stephen R. Lane, Doylestown, PA (US);
Assignee:
Bristol-Myers Squibb Company, Princeton, NJ (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/337 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 31/337 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01);
Abstract
The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.